Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Advises Companies To Pay Close Attention to Raw Materials In Cell Therapy Manufacture

Executive Summary

FDA officials attempt to clear up questions on regulatory expectations for qualifying raw materials for cell and gene therapy products. FDA officials advise manufacturers to conduct risk assessments, use the highest-grade materials they can find and avoid using animal-derived raw materials. Industry officials describe complexities in making these products.

You may also be interested in...



Immuno-Oncology Outlook: PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Novartis CAR-T AdComm Was Smooth Sailing, But Will That Be An Anomaly?

Other CAR-T sponsors can only hope for the same kind of US FDA advisory committee success that Novartis enjoyed with tisagenlecleucel, an outcome that reflected the sponsor's experience and preparation, a lack of major show-stopping safety or product quality concerns, and robust efficacy in a narrow pediatric population.

Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines

Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel